MAPT and Alzheimer disease: The first one is lithium, which has multiple mechanisms of action, such as downregulating NMDA receptor activity and increasing GABAergic transmission, and has been shown to inhibit GSK-3β, reduce tau phosphorylation, lower Aβ production and restore memory deficits in AD transgenic mouse models [191], (Figure 2, label 5, 13).